NRIX Stock — Nurix Therapeutics Inc.: Cash, EV, Pipeline

What they do

Our wholly owned, clinical stage pipeline includes three investigational drug candidates designed with the goal to be first-in-class or best-in-class therapeutics: bexobrutideg (NX-5948), a highly selective degrader of Bruton’s tyrosine kinase (BTK); zelebrudomide (NX-2127), a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells.

Source: 10-K FY2025 via SEC EDGAR

Share price

$15.30

Market cap

$1,671.5M

Cash

$1,063.1M

Enterprise value

$608.4M

Balance sheet

Cash	$1,063.1M
Debt	$0.0M
Net cash	$1,063.1M
Enterprise value	$608.4M
Basic shares	109.2M shares
Fully diluted shares	122.2M shares
Fully diluted market cap	$1,870.3M
Cash per share	$9.73
Quarterly burn	+$615.6M generated

Cash figures as of 2026-08-31. Database snapshot: 2026-11-07.

Share structure

Common

103.8M

Pre-funded warrants

0.0M

Options

13.1M

RSUs

3.1M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.3M

FDSO

122.2M

Cap table as of 2026-05-31.

Price history

Loading NRIX daily closes…

Loading price history…

Next catalyst

NX-1607 · Now - Nov 23, 2026 Now · Phase 1 · Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer

Recently reported

bexobrutideg (NX-5948) Mixed · 2026-06-11

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 23, 2026 Now	NX-1607	Phase 1	Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer	—
GUIDEDEst. Nov 7, 2026 Now guidance midpoint	bexobrutideg (NX-5948) Phase 1a/1b NX-5948-301 updates in relapsed/refractory CLL · NCT05131022	Phase 1a	relapsed/refractory CLL	throughout 2026
Feb 12 - Mar 26 in 14 wks	NX-5948	Phase 1	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Diffuse Large B Cell Lymphoma (DLBCL)	—
Feb 12 - Mar 25 in 15 mo	NX-5948	Phase 2	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)	—
Nov 12 - Dec 24 in 37 mo	NX-5948	Phase 3	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—
Jun 12 - Jul 24 in 80 mo	NX-5948	Phase 2	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

bexobrutideg

Phase 2 · Active Modality: protein degrader (small molecule)

Aliases NX-5948

Target BTK

Indications

Relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) (Phase 2)
Waldenstrom's macroglobulinemia (WM) (Stage not disclosed)

Status note BTK degrader. Phase 2 study in R/R CLL patients having failed three prior lines (cBTKi, BCL2i, ncBTKi) commenced Oct 2025. FDA Fast Track designated for R/R CLL/SLL (Jan 2024) and WM (Dec 2024); EMA PRIME designated for CLL/SLL (Nov 2024).

zelebrudomide

Phase 1 · Active Modality: protein degrader (small molecule)

Aliases NX-2127

Target BTK, IKZF1, IKZF3

Indications

Relapsed/refractory B-cell malignancies (Phase 1)

Status note Dual degrader of BTK and IKZF1/IKZF3. Phase 1a/1b dose-escalation and cohort expansion in R/R B-cell malignancies; enrollment paused in 2023 on partial clinical hold and recommenced Aug 2024. Dose escalation ongoing.

NX-1607

Phase 1 · Active Modality: small molecule inhibitor

Target CBL-B

Indications

Oncology (multiple indications) (Phase 1)

Status note CBL-B inhibitor. Phase 1a/1b dose-escalation and cohort expansion in a range of oncology indications. Awarded UK MHRA Innovation Passport in 2022.

NX-0479

Stage not disclosed · Active Modality: protein degrader (small molecule)

Aliases GS-6791

Target IRAK4

Partnerships Gilead Sciences (global strategic collaboration; Gilead licensed the IRAK4 degrader program)

Indications

not disclosed (Stage not disclosed)

Status note Clinical-stage IRAK4 degrader under the Gilead collaboration; Sanofi and Pfizer also hold protein-degradation collaborations (preclinical stage, targets undisclosed).

Per-asset detail extracted from the 10-Q filed 2026-07-09. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NX-5948
Lead indication	B-cell Lymphoma
Lead phase	Phase 3
Active trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07516093	Phase 3	Recruiting	Sponsor	NRIX	—	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—
NCT07221500	Phase 2	Recruiting	Sponsor	NRIX	—	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)	—
NCT07520006	Phase 2	Recruiting	Sponsor	NRIX	—	B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma	—
NCT05131022	Phase 1	Recruiting	Sponsor	NRIX	—	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Diffuse Large B Cell Lymphoma (DLBCL)	throughout 2026 Est. Nov 7, 2026 · guidance midpoint
NCT04830137	Phase 1	Recruiting	Sponsor	NRIX	—	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Waldenstrom Macroglobulinemia (WM)	—
NCT05107674	Phase 1	Recruiting	Sponsor	NRIX	—	Ovarian Cancer, Epithelial; Gastric Cancer; GastroEsophageal Junction (GEJ) Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Nurix Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	4,658,556	no change	0.57%	2026-08-14
Perceptive Advisors	4,320,422	+609,545	1.63%	2026-08-14
Braidwell LP	1,286,769	-463,997	1.15%	2026-08-14
ADAR1 Capital Management	313,236	+257,166	0.36%	2026-08-14
EcoR1 Capital	270,000	+270,000	0.32%	2026-08-14
Boxer Capital	100,000	no change	0.18%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

NRIX — Nurix Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

NRIX — Nurix Therapeutics Inc.